The OncLive Immunotherapy in Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in lung cancer. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment in non–small cell lung cancer and small cell lung cancer.
April 4th 2024
Data from the phase 2 KICKSTART trial of tomivosertib plus pembrolizumab do not support the combination's use in patients with non–small cell lung cancer.
Updated OS Analysis Favors Frontline Atezolizumab in PD-L1–High NSCLC
January 28th 2021January 28, 2021 - Atezolizumab demonstrated continued clinically meaningful benefits in overall survival, progression-free survival, overall response rate, and duration of response compared with chemotherapy in patients with PD-L1–high wild-type nonsquamous or squamous non–small cell lung cancer.
BMS-986012 Plus Nivolumab May Be Effective in Treating Relapsed/Refractory SCLC
January 28th 2021January 28, 2021 - Adding BMS-986012, anti–fucosyl-GM1 monoclonal antibody, to nivolumab demonstrated promising results in the treatment of patients with relapsed/refractory small cell lung cancer who did not receive previous checkpoint inhibitor therapy.
Frontline Pembrolizumab Maintains Survival Benefit Over Chemo in PD-L1+ NSCLC
January 28th 2021January 28, 2021 — Frontline pembrolizumab continued to demonstrate clinically meaningful improvements in overall survival, overall response rate, and time to progression on next-line therapy compared with platinum-based chemotherapy in patients with locally advanced or metastatic PD-L1–positive non–small cell lung cancer without sensitizing EGFR or ALK mutations.
Pembrolizumab Continues to Improve Survival in PD-L1–Positive Advanced NSCLC
January 28th 2021January 28, 2021 - Pembrolizumab continued to demonstrate a clinically meaningful improvement in overall and progression-free survival, compared with docetaxel, in patients with previously treated, PD-L1–positive advanced non-small cell lung cancer after more than 5 years of follow-up.
Pembrolizumab/Chemo Demonstrates Continued OS Improvement in Nonsquamous NSCLC
January 28th 2021January 28, 2021 — Pembrolizumab in combination with chemotherapy continued to show improved overall survival and progression-free survival compared with chemotherapy alone in patients with previously untreated metastatic nonsquamous non–small cell lung cancer.
Durvalumab, Osimertinib Envelop Adjuvant and Neoadjuvant NSCLC Treatment
January 25th 2021The sustained overall survival benefit with durvalumab and significant disease-free survival benefit benefit with osimertinib in the adjuvant setting represent major advances in the field of non–small cell lung cancer, fueling research with each modality in localized settings.
Advances in Immunotherapy in Metastatic Non–Small Cell Lung Cancer
January 8th 2021Non-small cell lung cancer is the most common histologic subtype of the disease, accounting for approximately 85% of cases. The recognition of targetable gene alterations and immune response has resulted in rapid changes to the therapeutic spectrum for NSCLC in recent years.
Immunotherapy Agents Drive Frontline Treatment Strategies in Advanced NSCLC
December 16th 2020Several immunotherapeutic options are available for non–small cell lung cancer (NSCLC), allowing decisions to be made based on histology, PD-L1 expression, and patient preference in regard to their treatment goals. Looking ahead, there may also be efficacy in moving immunotherapy drugs up into the resectable, early-stage setting
Immunotherapy Finds a Role in Frontline Small Cell Lung Cancer and Mesothelioma
December 14th 2020Checkpoint inhibitors have failed to improve progression-free survival and overall survival as second-line therapy and maintenance therapy in small cell lung cancer, but this class of agents continue to show encouraging activity worthy of a paradigm shift up front.
PD-L1 Status Stratifies Immunotherapy Treatment in NSCLC
November 25th 2020Data from completed studies evaluating immunotherapy in lung cancer alone or in combination with chemotherapy show that a breakdown of populations by PD-L1 status and additional considerations such as toxicity profiles should guide treatment decisions.
KEYNOTE-598 Trial Examining Pembrolizumab/Ipilimumab in NSCLC Stopped for Futility
The phase 3 KEYNOTE-598 trial evaluating the dual immunotherapy combination comprised of pembrolizumab and ipilimumab as frontline treatment in patients with metastatic non–small cell lung cancer who have a PD-L1 tumor proportion score of 50% or greater and do not harbor any EGFR or ALK aberrations has been discontinued.
Management of Small Cell Lung Cancer Moves Forward With Immunotherapy
November 7th 2020Frontline chemoimmunotherapy trials represent a critical milestone in extensive-stage small cell lung cancer, but one that requires better understanding of the methods that can be used to broaden the patient population in whom durable benefit is currently concentrated.